Skip to content

Association Between Irisin, Inflammatory Markers and Metabolic Status in Obese Children With Type 2 Diabetes Mellitus

Association Between Irisin, Inflammatory Markers and Metabolic Status in Obese Children With Type 2 Diabetes Mellitus

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03767608
Enrollment
40
Registered
2018-12-06
Start date
2016-01-31
Completion date
2017-01-31
Last updated
2018-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Pediatric Obesity

Brief summary

The objective of this study was to investigate the association of irisin with inflammatory markers as well with metabolic and anthropometric parameters in children and adolescents with type 2 diabetes mellitus compared with healthy controls.

Detailed description

Mexican children and adolescents previously diagnosed with type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria were recruited and compared to healthy controls. The participants will undergo: * vital signs measurement (systolic and diastolic blood pressure, heart rate, respiratory rate) * anthropometric variables measurement (BMI, weight, waist circumference, hip circumference, body fat %) * laboratory studies: glucose, triglycerides, HDL-c, C reactive protein, irisin After statistical analyses the investigators will compare the relationship of irisin and the inflammatory profile and the anthropometric parameters of diabetic patients versus lean controls.

Interventions

None listed

Sponsors

Instituto Tecnologico y de Estudios Superiores de Monterey
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years

Inclusion criteria

• Have been previously diagnosed with T2DM according to the American Diabetes Association (ADA) criteria . Healthy controls were required to have: * Normal weight according to the Centers for Disease Control and Prevention (CDC) criteria. * No metabolic abnormalities on blood samples * No previously diagnosed cardiometabolic diseases * Not been using antihypertensive, lipid or glucose lowering medications

Exclusion criteria

* Disapproval by the children's physician due to any at-risk medical condition known by the parents * Use of drugs for high blood pressure, hyperglycemia, or dyslipidemia

Design outcomes

Primary

MeasureTime frameDescription
Correlation of irisin levels and anthropometric parameters in children with type 2 diabetes mellitus (T2DM)1 dayCorrelation of irisin levels and anthropometric parameters in children with T2DM
Correlation of irisin levels and anthropometric parameters in healthy control children1 dayCorrelation of irisin levels and anthropometric parameters in healthy control children
Correlation of irisin levels and cytokines levels in children with T2DM1 dayCorrelation of irisin levels and cytokines levels in children with T2DM
Correlation of irisin levels and C reactive protein levels in healthy control children1 dayCorrelation of irisin levels and C reactive protein levels in healthy control children
Comparison between groups1 dayCompare the correlations of irisin woth anthropometric parameters and INFLAMMATORY MARKERSbetween children diagnosed with T2DM and healthy controls

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026